Equities analysts predict that Cerecor Inc (NASDAQ:CERC) will announce earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cerecor’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.18). Cerecor posted earnings per share of ($0.10) in the same quarter last year, which indicates a negative year over year growth rate of 60%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Cerecor will report full-year earnings of ($0.64) per share for the current fiscal year, with EPS estimates ranging from ($0.70) to ($0.59). For the next fiscal year, analysts forecast that the company will post earnings of ($0.64) per share, with EPS estimates ranging from ($0.65) to ($0.63). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Cerecor.

Cerecor (NASDAQ:CERC) last announced its earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Cerecor had a negative net margin of 226.50% and a negative return on equity of 120.67%. The business had revenue of $5.41 million during the quarter, compared to analyst estimates of $4.85 million.

Several brokerages have issued reports on CERC. ValuEngine lowered shares of Vereit from a “buy” rating to a “hold” rating in a research report on Friday. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $8.00 target price on shares of Cerecor in a research report on Tuesday, July 2nd. HC Wainwright set a $28.00 target price on shares of Denali Therapeutics and gave the company a “buy” rating in a research report on Monday, July 15th. TheStreet lowered shares of Virtusa from a “b-” rating to a “c+” rating in a research report on Wednesday, May 29th. Finally, Maxim Group began coverage on shares of Entera Bio in a research report on Tuesday, July 2nd. They set a “buy” rating and a $12.00 target price for the company. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Cerecor currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Cerecor stock traded down $0.07 during mid-day trading on Monday, hitting $4.53. 45,507 shares of the company traded hands, compared to its average volume of 138,596. Cerecor has a one year low of $2.71 and a one year high of $7.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.95 and a quick ratio of 0.91. The business’s fifty day moving average price is $5.10.

In other news, major shareholder Armistice Capital Master Fund bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were bought at an average cost of $4.97 per share, with a total value of $99,400.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Armistice Capital, Llc bought 18,200 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average cost of $4.64 per share, for a total transaction of $84,448.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 225,219 shares of company stock worth $1,077,864. 64.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Cerecor by 18.5% in the fourth quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock valued at $109,000 after acquiring an additional 5,293 shares in the last quarter. Northern Trust Corp boosted its holdings in Cerecor by 47.9% in the fourth quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock valued at $65,000 after acquiring an additional 6,500 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Cerecor by 50.7% in the fourth quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after acquiring an additional 31,951 shares in the last quarter. Opaleye Management Inc. bought a new stake in Cerecor in the fourth quarter valued at $6,212,000. Finally, Tibra Equities Europe Ltd bought a new stake in Cerecor in the first quarter valued at $210,000. 53.90% of the stock is currently owned by institutional investors.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

Recommended Story: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Cerecor (CERC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.